Patient-derived organoids in non-small cell lung cancer: advances in drug sensitivity testing
Wanyu Tang, Xudong Tian · 2026
Read Patient-derived organoids in non-small cell lung cancer: advances in drug sensitivity testing by Wanyu Tang, Xudong Tian (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12813125.txt.
Description
Wanyu Tang and Xudong Tian review, in a paper whose head dates it to 2025, patient-grown tumor organoids for drug testing in lung cancer. These mini-tumors keep the genetic and visible traits of the patient's own cancer. Older cell lines and animal grafts drift away from that fidelity.
Improved culture methods, gene editing, and freezing have made organoids more scalable and clinically relevant. They have exposed resistance tricks, such as one pathway behind drug failure. They have also revealed drug pairings with fresh promise. Modeling the tumor's surroundings remains a challenge, the authors note. Even so, organoids bring treatment choice closer to a test-before-you-treat routine.
Catalog record
| CREATOR | Wanyu Tang, Xudong Tian |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |